Cerus Corporation 10-Q Summary
Business context and reporting period
Cerus Corporation develops and commercializes the INTERCEPT Blood System for pathogen reduction in blood components. The platelet and plasma systems had CE marks and were marketed internationally; the red blood cell system remained in clinical development. This unaudited Form 10-Q covers the three months ended March 31, 2014, compared with the three months ended March 31, 2013. Cerus operated in one blood-safety segment.
Financial performance and liquidity
| Metric | Q1 2014 | Q1 2013 | Change |
|---|---|---|---|
| Product revenue | $7.9 million | $9.7 million | Down 19% |
| Gross profit | $3.7 million | $4.6 million | Down 20% |
| Gross margin | 47% | 48% | Down 1 percentage point |
| Research and development | $4.6 million | $2.7 million | Up 72% |
| SG&A | $8.2 million | $6.9 million | Up 20% |
| Loss from operations | $(9.2) million | $(5.0) million | Loss widened |
| Net loss | $(0.2) million | $(10.3) million | Improved primarily from warrant revaluation |
| Net cash used in operations | $(9.8) million | $(8.4) million | Use increased |
The Q1 2014 net loss included a $9.0 million non-cash gain from revaluation of the warrant liability, compared with a $5.1 million non-cash loss in Q1 2013. Excluding this volatile item, the underlying operating loss remained substantial. Net loss per basic share was approximately $0.00; diluted loss per share was $0.12, compared with $0.17 in Q1 2013. The filing reports 72.1 million basic weighted-average shares and 75.2 million diluted weighted-average shares for Q1 2014.
At March 31, 2014, cash and cash equivalents were $24.0 million and short-term investments were $24.3 million, for approximately $48.3 million of immediately available cash and investments. Total assets were $73.2 million, compared with $83.4 million at December 31, 2013. Working capital was $39.8 million. The company used $9.8 million in operating cash, spent $0.8 million on capital expenditures, received $3.0 million from investing activities primarily from investment maturities, and received $1.3 million from financing activities.
Debt consisted of $3.3 million outstanding under a revolving line of credit bearing interest at 4.75%. The facility was scheduled to mature on June 30, 2014 and required repayment of the outstanding balance unless amended or refinanced. Cerus was in compliance with its financial covenants at March 31, 2014, including a $2.5 million minimum cash balance and minimum revenue requirements.
Material changes versus the prior comparable period
- Revenue declined $1.9 million, primarily because of lower illuminator and disposable-kit sales to distributors.
- Gross margin declined modestly to 47%, mainly because of higher obsolescence charges, partially offset by lower disposable-kit costs.
- Research and development expense increased $1.9 million due to red blood cell clinical trials and FDA approval activities for the platelet and plasma systems.
- SG&A increased $1.4 million because of higher legal and corporate-service costs, stock-based compensation, and preparation for potential U.S. commercialization.
- The warrant liability declined from $20.4 million at year-end 2013 to $11.4 million at March 31, 2014, generating the $9.0 million non-cash gain.
- Cash and short-term investments decreased by approximately $9.4 million from December 31, 2013, reflecting operating cash burn and related payments.
- The 2013 amendment to the Fresenius supply agreement became effective January 1, 2014, providing fixed pricing and specified purchase obligations through December 31, 2018.
Guidance, outlook, risks and unusual items
Management expected near-term product revenue to remain relatively flat with 2013 levels, with disproportionate pressure in the first half of 2014 as the company transitioned certain distributor territories to new partners or a direct-sales model. Management expected research and development expense to continue increasing because of European Phase III red blood cell trials, a U.S. Phase II study, additional studies, and FDA PMA work. SG&A was also expected to rise as Cerus prepared for potential U.S. commercialization and expanded commercial resources.
The FDA was conducting substantive review of the plasma-system PMA, which had entered the stated 180-day review period. Cerus expected to submit the final module for the platelet-system PMA in the second quarter of 2014, subject to resolving FDA questions and completing an in vitro study. The red blood cell system required further clinical, development, regulatory and funding work, and was not commercialized.
Management stated that cash from product sales, available cash balances and debt access were expected to fund requirements for at least the next twelve months, but acknowledged that additional capital would be needed for longer-term development, particularly the red blood cell system. Potential equity financing could dilute shareholders. The company also noted that it may need to amend or replace the revolving credit facility when it matured in June 2014.
Key risks included limited market adoption and reimbursement, distributor transitions, dependence on Fresenius and other sole-source suppliers, manufacturing and inventory obsolescence, regulatory delays or failure to obtain FDA approvals, clinical-trial failure, continuing operating losses, need for additional financing, foreign-exchange exposure, product liability, intellectual-property disputes, and competition. Three customers represented approximately 65% of trade receivables at March 31, 2014, and two customers accounted for more than 10% of revenue: Etablissement Français du Sang at 23% and Movaco at 19%.
The filing reported no legal proceedings, no off-balance-sheet arrangements, and effective disclosure controls as of March 31, 2014.
Important facts for investors to verify
- Whether the June 30, 2014 revolving credit facility was extended, refinanced or repaid, and on what terms.
- Actual cash burn and remaining liquidity relative to the company’s development and commercialization plans.
- Progress, timing, deficiencies and ultimate outcomes of the FDA PMAs for the plasma and platelet systems.
- Revenue effects from distributor transitions and any shift to direct sales.
- Enrollment, results, costs and funding requirements for the red blood cell clinical programs.
- Future changes in the fair value of the warrant liability and the resulting volatility in reported earnings and diluted share calculations.
- Compliance with Fresenius purchase commitments and the effect of the amended supply agreement on gross margin, inventory and working capital.
- Dependence on major customers, distributors and sole-source manufacturers, including potential supply interruptions or product obsolescence.